The Neuro-Oncology Program has been an Established Research Program since 2005. The Program is led by a basic scientist, C. Stiles(DFCI), and a clinician, R. Martuza(MGH), both of whom bring years of leadership experience to their respective roles. The central focus of the Neuro-Oncology Program has been high grade-glioma in adults. The Program has a clinical trials portfolio that offers a range of therapeutic modalities for glioma, including: radiation, tumor vaccines, oncolytic viruses and signal transduction inhibitors. There are also two signal transduction pathways identified as areas of priority: VEGF antagonists and PI3K antagonists. Pediatric neuro-oncology is a growing area of interest. Genetically simple tumors of children have historically shed light on more common, genetically complex adult tumors. One of the significant strengths of the Neuro-Oncology Program in this regard is the presence of a strong pediatric oncology program anchored at DFCI for outpatient care and CHB, a nationally recognized pediatric hospital, for inpatient services, creating a unified pediatric oncology facility that has spanned both institutions for decades. Over the next five years, a goal is to move recent genetic insights from the bench to the bedside in order to improve the standard of clinical care and enable genetically-informed clinical trials. The Program plans to develop CLIA-certified assays for all """"""""actionable"""""""" genetic lesions in high-grade glioma and to apply these assays to every tumor resected at DF/HCC hospitals. There are 93 members in the Program drawn from all seven DF/HCC member institutions. They represent 13 departments of HMS and one department of HSPH. Collectively, members receive over $22.6 million in cancer-relevant funding, of which $8.1 million was from NCI and $10 million was from other peer-reviewed sponsors. During the project period (2006 to 2010), members published 997 articles in peer-reviewed journals, of which 18% were intra-programmatic, 33% were inter-programmatic, and 21% were interinstitutional. At the time of the CCSG renewal in 2005, the Program received a merit score of """"""""excellent to very good"""""""".
High-grade gliomas in adult patients are generally incurable. Collectively, these tumors are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between the ages of 15 and 34. The goal of the Neuro-Oncology Program is to improve the standard of care for patients with these tumors through genetically informed clinical trials (a.k.a. personalized medicine) conducted on a new generation of targeted therapeutics (a.k.a. smart drugs).
|Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:|
|Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028|
|Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318|
|Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682|
|Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503|
|Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288|
|Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547|
|Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268|
|Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359|
|Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727|
Showing the most recent 10 out of 371 publications